Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 2
1971 1
1973 1
1975 1
1976 2
1977 1
1978 2
1980 2
1984 1
1985 2
1986 4
1987 1
1988 1
1989 3
1990 4
1991 5
1992 3
1993 4
1994 2
1996 8
1997 4
1998 1
1999 1
2002 1
2003 2
2004 3
2005 4
2006 2
2007 1
2008 1
2009 1
2010 4
2011 6
2012 5
2013 3
2014 1
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Results by year
Filters applied: . Clear all
Page 1
Myocardial infarction: cardioprotection by erythropoietin
Talan MI and Latini R. Methods Mol Biol 2013. PMID 23456875 Free PMC article.
Results of several clinical trials in patients with acute MI completed to date failed to demonstrate beneficial effects of EPO, and thus put into question the validity of results obtained in animal models. ...This point was illustrated by the negative outcome of experiment in the rat model of MI in which timing of EPO administration was similar to that in clinical trials. ...
Results of several clinical trials in patients with acute MI completed to date failed to demonstrate beneficial effects of EPO, and t …
β₂ AR agonists in treatment of chronic heart failure: long path to translation
Talan MI, et al. J Mol Cell Cardiol 2011 - Review. PMID 20888833 Free PMC article.
Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β(2) AR agonist, fenoterol, in combination with a β(1) AR blocker, metoprolol, is more effective than β(1) AR blocker alone and as effective as β(1) AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. ...
Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of …
Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?
Talan MI, et al. PLoS One 2012. PMID 22529941 Free PMC article.
MI size was measured histologically 24 hrs after coronary occlusion. The area of myocardium at risk was similar among groups. ...The MI size was not affected by treatment administered 4 hrs after reperfusion or 6 hrs after permanent coronary occlusion. Therefore, our study in a rat experimental model of MI demonstrates that rhEPO administered within 2 hrs of a coronary occlusion effectively reduces MI size, but when rhEPO was administered following a delay similar to that encountered in clinical trials, it had no effect on MI size. ...
MI size was measured histologically 24 hrs after coronary occlusion. The area of myocardium at risk was similar among groups. ...The
Cardiovascular responses as behavior
Engel BT and Talan MI. Circulation 1991 - Review. PMID 1901257
Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window
Moon C, et al. Cardiovasc Drugs Ther 2005. Among authors: Talan MI. PMID 16187008
BACKGROUND: Recombinant human erythropoietin (rhEPO) protects tissue from ischemic damage, but translation of this finding into useful guidelines with respect to human trials for myocardial infarction (MI) requires a determination of the minimum effective rhEPO dose and the therapeutic window following MI. ...A 3000 IU/kg dose had similar therapeutic effects when delayed by 4, 8, or 12 h following MI, but was not effective after a 24-h delay. ...
BACKGROUND: Recombinant human erythropoietin (rhEPO) protects tissue from ischemic damage, but translation of this finding into useful guide …
Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy
Ahmet I, et al. J Pharmacol Exp Ther 2013. Among authors: Talan MI. PMID 23584743 Free PMC article.
Repeated echocardiography demonstrated remarkable attenuation of left ventricular dilatation (end-diastolic volume: 41 versus 86%; end-systolic volume: 44 versus 135%; P < 0.05), left ventricle functional deterioration (ejection fraction: -4 versus -63%; P < 0.05), and myocardial infarction (MI) expansion (3 versus 38%; P < 0.05). ...The results indicate that HBSP effectively reduces mortality, ameliorates the MI expansion and CHF progression, and preserves systolic reserve in the rat post-MI model. ...
Repeated echocardiography demonstrated remarkable attenuation of left ventricular dilatation (end-diastolic volume: 41 versus 86%; end-systo …
Fenoterol enantiomers do not possess beneficial therapeutic properties of their racemic mixture in the rat model of post myocardial infarction dilated cardiomyopathy
Ahmet I, et al. Cardiovasc Drugs Ther 2012. Among authors: Talan MI. PMID 22328006 Free PMC article.
PURPOSE: A salutary effect of β(2) adrenergic receptor (AR) agonist, fenoterol has been demonstrated in a rat model of post-myocardial infarction (MI) dilated cardiomyopathy (DCM). ...METHODS: Two weeks after induction of MI by permanent ligation of the anterior descending coronary artery early cardiac remodeling and MI size were assessed via echocardiography and rats were divided into treatment groups. ...
PURPOSE: A salutary effect of β(2) adrenergic receptor (AR) agonist, fenoterol has been demonstrated in a rat model of post-myocardial infar …
88 results
Jump to page
Feedback